menu
    • menu
    [{"orgOrder":0,"company":"Samson Clinical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Samson Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Samson Clinical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samson Clinical \/ Inapplicable"},{"orgOrder":0,"company":"Samson Clinical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Sulfonylurea receptor 2, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Samson Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Samson Clinical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Samson Clinical \/ Inapplicable"},{"orgOrder":0,"company":"Industrial Farmac\u00e9utica Cantabria","sponsor":"Bioskin | BioClever 2005","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Industrial Farmac\u00e9utica Cantabria","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Industrial Farmac\u00e9utica Cantabria \/ Bioskin | BioClever 2005","highestDevelopmentStatusID":"10","companyTruncated":"Industrial Farmac\u00e9utica Cantabria \/ Bioskin | BioClever 2005"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ViaDerma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"ViaDerma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViaDerma \/ Inapplicable"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ViaDerma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"ViaDerma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViaDerma \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Lili Legiawati","sponsor":"Indonesian Ministry of Research and Technology | National Research and Innovation Agency | PT KIMIA FARMA PERSERO TBK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Adipose-Derived Stem Cell","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Lili Legiawati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lili Legiawati \/ Indonesian Ministry of Research and Technology | National Research and Innovation Agency | PT KIMIA FARMA PERSERO TBK","highestDevelopmentStatusID":"10","companyTruncated":"Lili Legiawati \/ Indonesian Ministry of Research and Technology | National Research and Innovation Agency | PT KIMIA FARMA PERSERO TBK"},{"orgOrder":0,"company":"Triple Hair","sponsor":"Akums Drugs & Pharmaceuticals Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Dermatology","graph2":"Phase II","graph3":"Triple Hair","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd"},{"orgOrder":0,"company":"Aneira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Latanoprost","moa":"||Prostanoid FP receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Aneira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aneira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aneira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aneira Pharma","sponsor":"DataPharm Australia | CMAX Clinical Research | Agilex Australia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase I","graph3":"Aneira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aneira Pharma \/ DataPharm Australia | CMAX Clinical Research | Agilex Australia","highestDevelopmentStatusID":"6","companyTruncated":"Aneira Pharma \/ DataPharm Australia | CMAX Clinical Research | Agilex Australia"},{"orgOrder":0,"company":"Industrial Farmac\u00e9utica Cantabria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Sulfonylurea receptor 2, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Industrial Farmac\u00e9utica Cantabria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Industrial Farmac\u00e9utica Cantabria \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Industrial Farmac\u00e9utica Cantabria \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Lili Legiawati","sponsor":"Ministry of Education, Culture, Research, and Technology, Indonesia | PT KIMIA FARMA PERSERO TBK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"||Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Lili Legiawati","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Lili Legiawati \/ Ministry of Education, Culture, Research, and Technology, Indonesia | PT KIMIA FARMA PERSERO TBK","highestDevelopmentStatusID":"1","companyTruncated":"Lili Legiawati \/ Ministry of Education, Culture, Research, and Technology, Indonesia | PT KIMIA FARMA PERSERO TBK"}]

    Find Clinical Drug Pipeline Developments & Deals for Men''''s Rogaine

    Menu

    Men''''s Rogaine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy’s Launches Minoxidil for Women Following First-Ever Approval in India for The Treatment of Female ...

                            Details : Mintop (Minoxidil) topical solution has been approved in India for the treatment of alopecia in men (male pattern baldness), there are presently no other drugs approved for the treatment of FPHL in India.

                            Product Name : Mintop

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 09, 2021

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Samson Clinical

                            Country arrow
                            EPSC
                            Not Confirmed

                            Samson Clinical

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy & Safety of Minoxidil SL Tablets in Men With AGA

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 11, 2025

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Samson Clinical

                            Country arrow
                            EPSC
                            Not Confirmed

                            Samson Clinical

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Pharmacokinetic Study of Minoxidil SL Tablets

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 07, 2024

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Triple Hair

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Triple Hair

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Finasteride,Latanoprost,Minoxidil

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Akums Drugs & Pharmaceuticals Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Akums Drugs inks licensing pact with Canadian firm Triple Hair Inc

                            Details : Akums gains rights for patented topical formulation, Therapy-07, for the Indian market which combines three medicaments (finasteride,latanoprost,minoxidil) to combat alopecia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 16, 2024

                            Lead Product(s) : Finasteride,Latanoprost,Minoxidil

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Akums Drugs & Pharmaceuticals Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lili Legiawati

                            Country arrow
                            EPSC
                            Not Confirmed

                            Lili Legiawati

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Ministry of Education, Culture, Research, and Technology, Indonesia | PT KIMIA FARMA PERSERO TBK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hair Regeneration in Androgenetic Alopecia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 04, 2023

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Ministry of Education, Culture, Research, and Technology, Indonesia | PT KIMIA FARMA PERSERO TBK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Safety Shot

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Safety Shot

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jupiter Wellness Secures Foundational Patent Marking Milestone in Pursuit of Global Hair Loss Market

                            Details : JW-700 is a topical treatment designed to improve minoxidil efficacy which increases the enzymes needed for minoxidil to work, sulfotransferase enzymes, by up to 7x over a two-week period, for the treament of hair loss.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 05, 2023

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Industrial Farmacéutica Cantabria

                            Country arrow
                            EPSC
                            Not Confirmed

                            Industrial Farmacéutica Cantabria

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability Clinical Trial of Oral Minoxidil 1 mg

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 29, 2023

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ViaDerma

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            ViaDerma

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product

                            Details : Minoxidil may act as an 'epidermal growth factor' on matrix cells delaying their aging, thus prolonging the duration of the anagen phase via the activation of the beta-catenin pathway.

                            Product Name : Nupelo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 03, 2023

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Industrial Farmacéutica Cantabria

                            Country arrow
                            EPSC
                            Not Confirmed

                            Industrial Farmacéutica Cantabria

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Bioskin | BioClever 2005

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 05, 2023

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Bioskin | BioClever 2005

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aneira Pharma

                            Country arrow
                            EPSC
                            Not Confirmed

                            Aneira Pharma

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : DataPharm Australia | CMAX Clinical Research | Agilex Australia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 18, 2023

                            Lead Product(s) : Minoxidil,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : DataPharm Australia | CMAX Clinical Research | Agilex Australia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth